SIETES :: 93213 citas

Resultados de la búsqueda por AGRANULOCITOSIS REFINAR BÚSQUEDA

21.

Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satah T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang Y-K, for the ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97. [Ref.ID 89250]

22.

Munro AJ, Niblock PG. Cancer research in the global village. Lancet 2010;376:659-60. [Ref.ID 89243]

23.

Anónimo. Dobésilate de calcium: neutropénie (encore). Prescrire 2010;30:274. [Ref.ID 88322]

24.

Anónimo. Agranulocytosis associated with cocaine use - Four states, March 2008-November 2009. JAMA 2010;303:504-12. [Ref.ID 87820]

25.

Anónimo. Léflunomide + méthotrexate: risque d'atteintes respiratoires accru. Prescrire 2009;29:904. [Ref.ID 87337]

26.

Mérida Rodrigo L, Faus Felipe V, Poveda Gómez F, García Alegría J. Agranulocitosis por metamizol: un potencial problema en la población británica. Rev Clin Esp 2009;209:176-9. [Ref.ID 85884]

27.

Anónimo. Atypical antipsychotics and agranulocytosis. Canadian Adverse Reaction Newsleter 2009;19:1-2. [Ref.ID 85691]

28.

Aronson JK, Price D, Ferner RE. A strategy for regulatory action when new adverse effects of a licensed product emerge. Drug Saf 2009;32:91-8. [Ref.ID 85478]

29.

Schneeweiss S, Avorn J. Antipsychotic agents and sudden cardiac death - How should we manage the risk?. N Engl J Med 2009;360:294-6. [Ref.ID 84997]

30.

Hamerschlak N, Maluf E, Cavalcanti AB, Júnior AA, Eluf-Neto J, Falcâo RP, Lorand-Metze IGH, Goldenberg D, Santana CL, Rodrigues DOW, da Motta Passos LN, de Miranda Coelho EO, Pintâo MCT, de Souza HM, Borbolla JR, Pasquini R. Incidence and risk factors for agranulocytosis in Latin American countries - the Latin study. Eur J Clin Pharmacol 2008;64:921-9. [Ref.ID 84046]

31.

Andersohn F, Garbe E. Agranulocytosis induced by nonchemotherapy drugs. In response. Ann Intern Med 2008;148:320-1. [Ref.ID 82257]

32.

Mani S. Agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 2008;148:320. [Ref.ID 82256]

33.

Mossad SB. Agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 2008;148:320. [Ref.ID 82255]

34.

Ibáñez L, Vidal X, Laporte JR. Agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 2008;148:319-20. [Ref.ID 82254]

35.

Salem CB, Slim R, Hmouda H, Bouraoui K. Agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 2008;148:319. [Ref.ID 82253]

36.

Kontoghiorghes GJ. Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities. Expert Opin Drug Saf 2007;6:235-9. [Ref.ID 80688]

37.

Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 2007;146:657-65. [Ref.ID 80061]

38.

Hsieh MM, Everhart JE, Byrd-Holt DD, Tisdale JF, Rodgers GP. Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences. Ann Intern Med 2007;146:486-92. [Ref.ID 79741]

39.

Tavassoli N, Duchayne E, Sadaba B, Desboeuf K, Sommet A, Lapeyre-Mestre M, Muoz MJ, Sie P, Honorato J, Montastruc J-L, Bagheri H. Detection and incidence of drug-induced agranulocytosis in hospital: a prospective analysis from laboratory signals. Eur J Clin Pharmacol 2007;63:221-8. [Ref.ID 79523]

40.

Ibáñez Ruiz C, Albarracín Serra A. Farmacovigilancia en el CMBD. Boletín Informativo del Centro de Farmacovigilancia de la Comunidad de Madrid 2006;13:1-7. [Ref.ID 79466]